Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Sharmilan, Thanendrarajan"'
Autor:
Yan Cheng, Fumou Sun, Daisy V. Alapat, Visanu Wanchai, David Mery, Eric R. Siegel, Hongwei Xu, Sarah Johnson, Wancheng Guo, Clyde Bailey, Cody Ashby, Michael Anton Bauer, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Tumor immune microenvironmental alterations occur early in multiple myeloma (MM) development. In this study, we aim to systematically characterize the tumor immune microenvironment (TME) and the tumor-immune interactions from precursor stage
Externí odkaz:
https://doaj.org/article/e8dd857feedf48c5930d5a49c2504046
Autor:
Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan, Maurizio Zangari, Frits vanRhee, Carolina Schinke, Samer Al Hadidi
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 789-792 (2024)
Abstract Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15%
Externí odkaz:
https://doaj.org/article/522f7477b16041b9b67794b001078928
Autor:
Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits vanRhee, Samer Al Hadidi
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 554-559 (2024)
Abstract Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of
Externí odkaz:
https://doaj.org/article/c4e60f609498470e9d4ed1b0a87d5646
Autor:
Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D’Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and incl
Externí odkaz:
https://doaj.org/article/d351607332e14f5bb21b5075a7aac379
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Autor:
Wancheng Guo, Yihao Zhan, David Mery, Eric R. Siegel, Fumou Sun, Yan Cheng, Timothy Cody Ashby, Zijun Zhang, Clyde Bailey, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/f59b8168c4bc41abb2bfff80fe089e06
Autor:
Fumou Sun, Yan Cheng, Visanu Wanchai, Wancheng Guo, David Mery, Hongwei Xu, Dongzheng Gai, Eric Siegel, Clyde Bailey, Cody Ashby, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Yupo Ma, Qing Yi, Robert Z. Orlowski, Maurizio Zangari, Frits van Rhee, Siegfried Janz, Gail Bishop, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR-T c
Externí odkaz:
https://doaj.org/article/68fd54c5690048f79c63bc21afccca4b
Autor:
Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz, Bart Barlogie, Frits Van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting MGUS progression has not been p
Externí odkaz:
https://doaj.org/article/06fafe2671dd496cac7b712408124b7b
Autor:
Faris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy Jr, Fenghuang Zhan, Frits vanRhee, Samer Al Hadidi
Publikováno v:
eJHaem, Vol 4, Iss 2, Pp 454-458 (2023)
Abstract The definition of high‐risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme v
Externí odkaz:
https://doaj.org/article/092efc3f964b4af8aef42ba95eaf4704
Autor:
Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra, Divaya Bhutani, Sharmilan Thanendrarajan, Siegfried Janz, Maurizio Zangari, Suzanne Lentzsch, Frits van Rhee, Juan Carlos Rico Crescencio, Anita D’Souza, Rajshekhar Chakraborty, Meera Mohan, Carolina Schinke
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA) and GPRC5D bispecific antibodies (bsAb) in relapsed/refractory multiple myeloma (RRMM). The aim of our multi-institutional study was to characterize the incid
Externí odkaz:
https://doaj.org/article/d532fb16c58f485e96a6b79a1fe6f080
Autor:
Leo Rasche, Carolina Schinke, Francesco Maura, Michael A. Bauer, Cody Ashby, Shayu Deshpande, Alexandra M. Poos, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Brian A. Walker, Bart Barlogie, Ola Landgren, Gareth J. Morgan, Frits van Rhee, Niels Weinhold
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Spatially and temporally resolved data can improve our understanding of evolution and treatment resistance in multiple myeloma (MM). Here, the authors analyse spatial and longitudinal heterogeneity in MM patients using multi-region sequencing, and id
Externí odkaz:
https://doaj.org/article/832c8c194632414993cfa4d014438ce1